Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
| Line 15: | Line 15: | ||
*[[Media:2020_05-26_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|May 26, 2020]] | *[[Media:2020_05-26_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|May 26, 2020]] | ||
*[[Media:2020_04-28_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 28, 2020]] | *[[Media:2020_04-28_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|April 28, 2020]] | ||
| − | |||
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | ||
Revision as of 15:03, 29 July 2020
- Co-chairs: Thomas M. Link, MD, PhD; Xiaojuan Li, PhD
- RSNA Staff Support: Susan Stanfa
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive
Working Documents
- QIBA MSK Profile 2020-01-28: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease